scholarly journals Some biological characteristics and features of the mitotic regime of basal-like breast cancer living in the south-east of Ukrainе

2016 ◽  
Author(s):  
T. Yu. Pogorеlaya ◽  
N. F. Shchurov
Keyword(s):  
Breast Cancer ◽  
Ductal Carcinoma ◽  
Molecular Genetic ◽  
Current Treatment ◽  
Low Grade ◽  
The South ◽  
Ki 67 ◽  
Treatment Regimens ◽  
Basal Like Breast Cancer ◽  
High Degree

Current treatment regimens for patients with breast cancer should consider molecular genetic type of tumor. To identify aggressive tumors in medical practice assess the proliferation marker Ki-67 and apoptosis marker p53, but there are no data about its prognostic value in patients BLBC living in the south-east ofUkraine. For low-grade tumors, which include BLBC, characterized by a high degree of mitotic activity. In patients with BLBC in more than 50 % cases there was detected infiltrating ductal carcinoma. The high degree of aggression BLBC in the south-east ofUkraineputs its study on a par with the major problems in oncoecology.

scholarly journals Clinical, morphological, and molecular genetic predictors of metastatic lesions in the regional lymph nodes in breast cancer

2018 ◽  
Vol 5 (3) ◽  
pp. 8-16
Author(s):  
Yu. A. Dergunova ◽  
V. V. Podionov ◽  
V. K. Bozhenko ◽  
V. V. Kometova ◽  
M. V. Dardyk
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Nodes ◽  
Molecular Genetic ◽  
Regional Lymph Nodes ◽  
Genetic Characteristics ◽  
Metastatic Lesions ◽  
Genetic Predictors ◽  
Node Metastases ◽  
High Degree

Despite the sufficient amount of data accumulated in the literature, there are still no factors, on the basis of which it would be possible to estimate the regional lymph nodes status in breast cancer with a high degree of accuracy. The review presents literature data relating to the influence of clinicopathological, molecular-biological and genetic characteristics of primary tumor on lymph node metastases. Data of 66 foreign and Russian articles are included.

Histological Assessment of Breast Lesions Identified Exclusively by Magnetic Resonance

2014 ◽  
Vol 80 (10) ◽  
pp. 944-947
Author(s):  
Victoria O'connor ◽  
Elizabeth Arena ◽  
Joslyn Albright ◽  
Nefertiti Brown ◽  
Ryan O'connor ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Magnetic Resonance ◽  
Breast Biopsy ◽  
Ductal Carcinoma ◽  
Low Grade ◽  
Breast Lesions ◽  
Significant Family History ◽  
Ductal Hyperplasia ◽  
Significant Pathology

Radiologic–pathologic correlation of lesions diagnosed by magnetic resonance (MR) is precluded by insufficient data on histological characteristics of lesions suspicious on MR but not visible on concurrent mammogram or ultrasound. The objective of this study was to describe histological features of breast lesions diagnosed exclusively by MR. The participants underwent MR-guided breast biopsy between 2007 and 2012 for a suspicious lesion not identified by mammography or ultrasound. Histology slides were interpreted retrospectively by a breast pathologist. Of 126 patients (126 lesions), 34 (27%) had new breast cancer, 51 (40.5%) previous breast cancer, and 41 (32.5%) dense breasts or a significant family history of breast cancer. MR identified 23 (18.3%) invasive cancers: 20 were Grade 1 and 17 were ductal. Of the 126 lesions, 16 (13%) were ductal carcinoma in situ (DCIS), four were atypical ductal hyperplasia and atypical lobular hyperplasia (3%), and 68 (54%) were benign. Fifteen biopsies (12%) had no significant pathology. Five DCIS lesions were upgraded to T1 invasive cancers. Approximately 30 per cent of suspicious lesions detected exclusively by MR are invasive or in situ cancers that are predominantly low grade. Further studies are needed to determine if malignant lesions can be prospectively distinguished by MR characteristics.

Immunotherapy of Advanced Breast Cancer With a Heterophilic Ganglioside (NeuGcGM3) Cancer Vaccine

2003 ◽  
Vol 21 (6) ◽  
pp. 1015-1021 ◽  
Author(s):  
Adriana Carr ◽  
Edmundo Rodríguez ◽  
María del Carmen Arango ◽  
Rolando Camacho ◽  
Marta Osorio ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Vaccine ◽  
Ductal Carcinoma ◽  
Serum Antibody ◽  
World Health ◽  
Stage Iii ◽  
Induction Phase ◽  
Low Grade ◽  
Breast Cancer Patients ◽  
Monthly Basis

Purpose: A heterophilic ganglioside cancer vaccine was developed by combining NeuGcGM3 with the outer membrane protein complex of Neisseria meningitidis to form very small size proteoliposomes (VSSP). A phase I clinical trial was performed to determine safety and immunogenicity of this vaccine. Patients and Methods: Stage III to IV breast cancer patients received up to 15 (200 μg) doses of the vaccine by intramuscular injection. The first five doses (induction phase) were given at 2-week intervals, with the remaining treatment (maintenance) administered on a monthly basis. Results: Twenty-one patients, 11 of whom had metastatic disease, were included. Main toxicities included erythema and induration at the injection site, sometimes associated with mild pain, and low-grade fever (World Health Organization grades 1 and 2). All treated patients who completed the induction phase developed anti-NeuGcGM3 antibody titers between 1:1,280 and 1:164,000 immunoglobulin G (IgG), and 1:640 and 1:164,000 IgM. Noteworthy specific IgA antibodies were induced by vaccination in all stage III patients and in three stage IV patients. Serum antibody levels were higher in the stage III patients, with the larger increases observed after week 32. The antiganglioside IgG subclasses were mainly IgG1 and IgG3. Hyperimmune sera increased complement-mediated cytotoxicity versus P3X63 myeloma cells and a marked IgG differential reactivity against human mammary ductal carcinoma samples. Conclusion: NeuGcGM3/VSSP/Montanide ISA 51 is an unusual immunogenic ganglioside vaccine and also seems to be safe in this small trial. Immunologic surrogates of activity indicate that this reagent warrants further investigation.

scholarly journals Neuroendocrine Differentiation in Breast Cancer: Clinicopathological Significance of Bcl-2 Positive Solid Papillary Carcinoma

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Yoichiro Okubo ◽  
Takuji Okubo ◽  
Yoshimi Okubo ◽  
Takao Ishiwatari
Keyword(s):  
Breast Cancer ◽  
Papillary Carcinoma ◽  
Neuroendocrine Tumors ◽  
Ductal Carcinoma ◽  
Neuroendocrine Differentiation ◽  
Prognostic Indicator ◽  
Low Grade ◽  
Term Survival ◽  
Solid Papillary Carcinoma ◽  
Poor Prognostic Indicator

Solid papillary carcinoma (SPC) is considered a rare malignant breast tumor. Maluf and Koerner first reported this disease entity as a special type of ductal carcinoma in situ with several characteristic histopathological features, including low-grade cellular atypia, intracellular or extracellular mucin deposition, and solid papillary growth pattern, as well as neuroendocrine differentiation. The present paper describes a case of SPC with bcl-2 expression, which is known as a marker for malignancy of neuroendocrine tumors. Interestingly, despite bcl-2 expression being a poor prognostic indicator of neuroendocrine tumors, the patient with this tumor has achieved long-term survival (approximately 6 years) at the time of writing this report. Because previous investigators reported that bcl-2 expression might play a role in the inhibition of the development of breast cancer, we suggest that bcl-2 expression might reflect a good prognosis in patients with SPC, rather than being a poor prognostic indicator, as it is in several types of neuroendocrine tumor. However, to confirm this hypothesis, further investigation is required.

scholarly journals The Expressions of Wnt/β-catenin Pathway-Related Components in Brainstem Gliomas

2013 ◽  
Vol 40 (3) ◽  
pp. 355-360 ◽  
Author(s):  
Wenhao Wu ◽  
Yongji Tian ◽  
Hong Wan ◽  
Yongmei Song ◽  
Junhua Li ◽  
...  
Keyword(s):  
Signaling Pathway ◽  
Clinicopathological Characteristics ◽  
Current Treatment ◽  
Brainstem Glioma ◽  
Low Grade ◽  
Normal Brain ◽  
Ki 67 ◽  
Significant Difference ◽  
The Relationship ◽  
Brain Tissues

Background:The overall prognosis of brainstem gliomas is very poor, and the current treatment cannot significantly prolong the overall survival of these patients; therefore, studying the molecular biological mechanisms of the occurrence and development of brainstem gliomas has important significance for their treatment. The Wnt/β-catenin signaling pathway is closely associated with the occurrence and development of tumors, but its relationship with brainstem gliomas remains unclear.Methods:This study used Western blot and immunohistochemistry methods to detect the expressions of Wnt/β-catenin signaling pathway-related components such as Wnt-1, Wnt-2, β-catenin and C-myc in six cases of normal brain tissues and 24 cases of brainstem gliomas and analyzed the relationship between their expressions and clinicopathological characteristics.Results:Wnt-1 had no obvious expression in normal brain tissues and did not show any significant difference between high- and low-grade brainstem gliomas; the expressions of Wnt-2, β-catenin and C-myc in high-grade brainstem gliomas were significantly higher than that in low-grade brainstem gliomas and normal brain tissues and were positively correlated with the expression of Ki-67. Moreover, the expressions of Wnt-2 and C-myc were significantly associated with the prognosis of brainstem glioma patients; additionally, there was a trend toward increased β-catenin expression with shorter survival, but there was no statistical difference.Conclusions:Wnt/β-catenin signaling pathway might be abnormally activated and plays an important role in the occurrence and development of brainstem gliomas. Wnt-2, β-catenin and C-myc may be potential targets for brainstem glioma treatment.

scholarly journals Comparison of the Distribution Pattern of 21-Gene Recurrence Score between Mucinous Breast Cancer and Infiltrating Ductal Carcinoma in Chinese Population: A Retrospective Single-Center Study

2020 ◽  
Vol 52 (3) ◽  
pp. 671-679
Author(s):  
Jiayi Wu ◽  
Shuning Ding ◽  
Lin Lin ◽  
Xiaochun Fei ◽  
Caijin Lin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Distribution Pattern ◽  
Ductal Carcinoma ◽  
Molecular Subtype ◽  
Disease Free Survival ◽  
Recurrence Score ◽  
Chinese Patients ◽  
Ki 67 ◽  
Infiltrating Ductal Carcinoma ◽  
Mucinous Breast Cancer

PurposeThis retrospective study aimed to evaluate the distribution pattern and prognostic value of 21-gene recurrence score (RS) in Chinese patients with mucinous breast cancer (MC) and compared with infiltrating ductal carcinoma (IDC).Materials and MethodsPatients diagnosed with MC or IDC from January 2010 to January 2017 were retrospectively recruited. Reverse transcriptase–polymerase chain reaction assay of 21 genes was conducted to calculate the RS. Univariate and multivariate analyses were performed to assess the association between RS and clinicopathological factors. Survival outcomes including disease-free survival (DFS) and overall survival (OS) were estimated by Kaplan-Meier method and compared by log-rank test.ResultsThe MC cohort included 128 patients and the IDC cohort included 707 patients. The proportions of patients with a low (RS < 18), intermediate (18-30), or high risk (RS > 30) were 32.0%, 48.4%, and 19.5% in MC cohort, and 26.9%, 46.8% and 26.3% in IDC cohort. The distribution of RS varied significantly according to different Ki-67 index and molecular subtype in both cohorts. Moreover, the receipt of chemotherapy was associated with RS in both cohorts. Among patients with MC, tumor stage was related to the DFS (p=0.040). No significant differences in DFS and OS were found among MC patients in different RS risk groups (OS, p=0.695; DFS, p=0.926).ConclusionRS was significantly related to Ki-67 index and molecular subtypes in MC patients, which is similar in IDC patients. However, RS was not able to predict DFS and OS in patients with MC.

scholarly journals Morphological features of tumor in different treatment options for patients With Locally Advanced Breast Cancer

2020 ◽  
Vol 1 (7) ◽  
pp. 105-107
Author(s):  
Narzieyva D.F ◽  
Jonibekov J.J ◽  
Erkinova Sh.N
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Locally Advanced Breast Cancer ◽  
Treatment Options ◽  
Molecular Genetic ◽  
Locally Advanced ◽  
Morphological Structure ◽  
Advanced Breast ◽  
Ki 67 ◽  
The Republic

Despite significant advances in the early diagnosis and treatment of locally advanced breast cancer, 60–65% of the Republic of Uzbekistan is accounted for by locally advanced breast cancer and its mortality rate is high. The morphological structure of breast cancer is important for the prognosis of the disease. On cell membranes there are special cytoplasmic proteins - receptors, which, when combined with hormones, can affect the rate of division of tumor cells. In terms of the choice of treatment options and the assessment of the forecast, some molecular genetic parameters of the tumor are important, among which, first of all, the hormonal status of the tumor (ER / PR), HER-2 / neu, p53, Bcl-2, Ki-67

scholarly journals Immunohistochemical characteristics of breast cancer, increasing the risk of local reccurence after organosaving treatment

2018 ◽  
Vol 14 (3) ◽  
pp. 10-14
Author(s):  
S. M. Demidov ◽  
D. A. Demidov ◽  
S. V. Sazonov ◽  
E. I. Churakova
Keyword(s):  
Breast Cancer ◽  
Proliferative Activity ◽  
Receptor Gene ◽  
Molecular Genetic ◽  
Statistical Processing ◽  
Immunohistochemical Analysis ◽  
Recurrent Tumor ◽  
Ki 67 ◽  
Epidermal Growth ◽  
Triple Negative Subtype

Objective:an immunohistochemical analysis of the characteristics of a recurrent tumor in breast cancer.Materials and methods.The statistical processing of immunohistochemical analysis’ results was performed and the most frequently encountered molecular-genetic subtypes of breast cancer with the development of local relapses were formulated. The analysis used a standard immunohistochemical panel, which is the “gold standard” for diagnostic in Russia today, and includes the expression of receptors for sex hormones (estrogen and progesterone), expression of the human epidermal growth factor HER2/neu receptor gene, and the index of proliferative activity Ki-67. The 2nd stage of the work was the evaluation of the dynamics of changes in the immunohistochemical characteristics of a recurrent tumor in comparison with the primary one.Results and conclusion.The most common local recurrence provides by triple-negative subtype of breast cancer (42 %). The changes in the immunohistochemical characteristics of a recurrent tumor in comparison with the primary one affected only the index of proliferative activity Ki-67 in the direction of its increase by 12 %.

scholarly journals Monoclonal Antibodies for Immunohistochemical Diagnosis of Breast Cancer

2021 ◽  
Vol 15 (1) ◽  
pp. 157-163
Author(s):  
Aigerim Turgimbayeva ◽  
Assel Issabekova ◽  
Assylbek Zhylkibayev ◽  
Saule Eskendirova
Keyword(s):  
Breast Cancer ◽  
Monoclonal Antibodies ◽  
Molecular Genetic ◽  
Tumour Response ◽  
Progesterone Receptors ◽  
Pass Rate ◽  
Ki 67 ◽  
Proliferation Markers ◽  
Expression Levels ◽  
Immunohistochemical Diagnosis

Breast cancer is a leading malignant disease in women worldwide, although its pathology is visually localised. Currently, it has been proven that the parameters of molecular genetic biomarkers, including oncoprotein HER2, proliferation markers Ki-67, oestrogen receptors ER, and progesterone receptors PgR, are associated with breast carcinogenesis and are a reflection of the biological aggression of the tumour. The significance of these biomarkers in signalling pathways and genetic mechanisms of carcinogenesis has been described, as well as the relationship between the expression levels of each biomarker and the tumour response to appropriate therapy. The primary antibody that imparts specificity to IHC is based on the monoclonal antibodies (mAbs) as the main immunoreagent that enables reliable identification of breast cancer cells. The most commonly used antibodies to molecular biomarkers for IHC were determined in accordance with indicators of laboratory use and efficiency (pass rate) of HER2, Ki-67, ER, PgR assessments in the NordiQC breast cancer module. The discovery of the complete structure of these biomarkers and the design of their domains and subdomains by genetic engineering methods enable the synthesis of effective monoclonal antibodies. Quantitative indicators of the expression levels of tumour biomarkers of breast cancer were determined using mAb, depending on epitope specificity and affinity.

scholarly journals Basal-Like Breast Cancer; Clinicopathological, Molecular, and Prognostic Features

2019 ◽  
pp. 85-91
Author(s):  
Sabrine Haddad ◽  
Ines Zemni ◽  
Irtyah Merchaoui ◽  
Ilhem Bettaib ◽  
Olfa Adouni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Poor Prognosis ◽  
Ductal Carcinoma ◽  
Disease Free Survival ◽  
Distant Metastases ◽  
Metaplastic Carcinoma ◽  
Breast Cancers ◽  
Ki 67 ◽  
Prognostic Features ◽  
The Mean

Background: Molecular classification of breast tumors has identified the basal-like subtype, with high heterogeneity and very poor prognosis. These tumors are mainly triple negative, characterized by the expression of basal markers CK5/6 and EGFR. In this study, we sought to investigate the features, outcome, and therapeutic modalities of basal-like breast cancers (BLBC).Methods: We retrospectively identified 90 BLBC patients diagnosed at the Department of Surgical Oncology of Salah Azaiez Institute between January 2009 and December 2013. Results: The mean age of our patients was 50 years, and 15.5% had a family history of breast cancer. The mean tumor size was 43.8 mm. Histological examination revealed invasive ductal carcinoma in 88.9% of the cases, metaplastic carcinoma in 5.6%, and medullary carcinoma and adenoid cystic carcinoma in 2.2%. BLBC was most often associated with a high tumor grade (55.3% had a grade 3 tumor) and a high Ki-67 proliferative index. Vascular invasion was found in 31.1% of the cases. Regarding lymph node involvement, 42.9% had positive lymph nodes and 7.9% featured distant metastases. Surgical treatment was provided for 85 patients. It consisted of conservative surgery in 40 cases and radical surgery in 45 cases. Neoadjuvant chemotherapy was administrated to 23 patients, with a 13% complete pathologic response. The rates of overall survival and disease-free survival at 3 years for localized BLBC were 74.4% and 75.9%, respectively. Conclusion: BLBCs are aggressive tumors associated with poor prognosis. Thus, to identify novel prognostic factors and therapeutic targets, prospective studies should investigate the epidemiological and evolutive profile of these tumors.

Sign in / Sign up

Export Citation Format

Share Document